Education, Science, Technology, Innovation and Life
Open Access
Sign In
  1. Home
  2. Journals
  3. MEDS Chinese Medicine
  4. Vol 7, Issue 1, 2025

α-Synuclein's Multifunctionality in Parkinson's Disease: From Pathogenic Mechanisms to Therapeutic Targets

Download as PDF

DOI: 10.23977/medcm.2025.070103 | Downloads: 12 | Views: 460

Author(s)

Yu Ruishan 1, He Jiaqi 1, Du Nan 1, Peng Tao 1, Wang Gaofen 1

Affiliation(s)

1 Shaanxi University of Chinese Medicine, Xianyang City, Shaanxi Province, China

Corresponding Author

Yu Ruishan

ABSTRACT

Parkinson's disease (PD), a prevalent neurodegenerative disorder, affects over 6 million individuals worldwide. Its incidence rates are positively correlated with age, showing an increasing trend as age advances. α-Synuclein plays a central role in the initiation and progression of Parkinson's disease. The mechanisms underlying its transition from a physiological to a pathological state are highly complex and diverse. This article conducts an in-depth investigation of α-synuclein, providing a detailed analysis of its molecular structural characteristics and physiological functions. It focuses on elucidating its pathological mechanisms in the progression of Parkinson's disease, including aggregation and fibrillation, effects on cellular organelles, induction of neuroinflammation, and cell death. Additionally, it offers a comprehensive review of current therapeutic strategies targeting α-synuclein, aiming to provide new insights and directions for the treatment of Parkinson's disease and to promote further research and development in related fields.

KEYWORDS

α-synuclein, Parkinson's disease, pathogenic mechanisms, therapeutic targets

CITE THIS PAPER

Yu Ruishan, He Jiaqi, Du Nan, Peng Tao, Wang Gaofen, α-Synuclein's Multifunctionality in Parkinson's Disease: From Pathogenic Mechanisms to Therapeutic Targets. MEDS Chinese Medicine (2025) Vol. 7: 14-21. DOI: http://dx.doi.org/10.23977/medcm.2025.070103.

REFERENCES

[1] Zhang Z, Roman G, Hong Z, et al. Parkinson’s disease in China: Prevalence in Beijing, Xian, and Shanghai [J]. Lancet, 2005, 365(9459): 595 - 597.
[2] De Lau L M, Breteler M M. Epidemiology of Parkinson’s disease [J]. Lancet Neurol, 2006, 5(6): 525 - 535.
[3] Alves G, Forsaa E B, Pedersen K F, et al. Epidemiology of Parkinson's disease [J]. J. Neurol, 2008, 255(5): 18 - 32.
[4] Wang J Y, Ren B B, Ma S N, et al. Mechanism of α-synuclein -induced mitochondrial damage in Parkinson's disease [J]. Chinese Journal of Tissue Engineering Research, 2025, 29(17): 3668 - 3674.
[5] Hallacli E, Kayatekin C, Nazeen S, et al. The Parkinson's disease protein alpha - synuclein is a modulator of processing bodies and mRNA stability[J]. Cell, 2022, 185(12): 2035 - 2056.
[6] Zhang S, Zhu R, Pan B, et al. Post - translational modifications of soluble α - synuclein regulate the amplification of pathological α – synuclein [J]. Nat Neurosci, 2023, 26(2): 213 - 225.
[7] Tong J, Huang Y T, Li L X, et al. New research progress on the physiological functions and pathological roles of α-synuclein [J]. China Medical Herald, 2024, 37(3): 18 - 26. DOI: 10.19296/j.cnki.1008 - 2409.2024 - 03 - 003.
[8] Bendor JT, Logan TP, Edwards RH. The function of α - synuclein. Neuron, 2013, 79(6): 1044 - 1066.
[9] Burre J, Sharma M, Tsetsenis T, et al. c Alpha - synuclein promotes SNARE - complex assembly in vivo and in vitro. Sciene, 2010, 329(5999): 1663 - 1667.
[10] SIMON C, SOGA T, OKANO HJ, et al. α - Synuclein - mediated neurodegeneration in Dementia with Lewy bodies: the pathophysiology of a paradox. Cell Biosci. 2021; 11(1):196. 
[11] MALPARTIDA AB, WILLIAMSON M, NARENDRAP D, et al. Mitochondrial Dysfunction and Mitophagy in Parkinson's Disease: From Mechanism to Therapy. Trends Biochem Sci. 2021; 46(4):329 - 343.
[12] Li Y H, Mou Z, Cui L H. Research progress on the regulation of the endoplasmic reticulum quality control system and its relationship with Parkinson's disease[J]. Advances in Physiological Science, 2024, 55(3): 278 - 284. DOI: 10.20059/j.cnki.pps.2023.11.1139.
[13] Cardinale A, Calabrese V, De Iure A, et al. Alpha - synuclein as a prominent actor in the inflammatory synaptopathy of Parkinson's disease. Int J Mol Sci, 2021, 22(12): 6517.
[14] Han S D, Cui M. Research progress on immunotherapy for synucleinopathies[J]. Chinese Journal of Clinical Neurosciences, 2018, 26(1): 86 - 95.
[15] Düchs, M., Blazevic, D., Rechtsteiner, P., Kenny, C., Lamla, T., Low, S., Savistchenko, J., Neumann, M., Melki, R., Schönberger, T., Stierstorfer, B., Wyatt, D., Igney, F., & Ciossek, T. (2023). AAV-mediated expression of a new conformational anti-aggregated α-synuclein antibody prolongs survival in a genetic model of α-synucleinopathies. NPJ Parkinson's disease, 9(1), 91. https://doi.org/10.1038/s41531-023-00542-9
[16] Yu H Y, Yan J J, Li W. Research progress on α-synuclein imaging agents and small molecule inhibitors as therapeutic drugs[J]. Journal of Shenyang Pharmaceutical University, 2022, 39(2): 233 - 242. DOI: 10.14066/j.cnki.cn21 - 1349/r.2020.0858.
[17] Sandoval, I. M., Marmion, D. J., Meyers, K. T., & Manfredsson, F. P. (2021). Gene Therapy to Modulate Alpha-Synuclein in Synucleinopathies. Journal of Parkinson's disease, 11(s2), S189–S197. https://doi.org/ 10.3233/JPD-212679
[18] Elkouzi, A., Vedam-Mai, V., Eisinger, R. S., & Okun, M. S. (2019). Emerging therapies in Parkinson disease - repurposed drugs and new approaches. Nature reviews. Neurology, 15(4), 204–223. https://doi.org/10.1038/s41582-019-0155-7 
[19] Sun S N, Xiao Q, Fan L S, et al. Current research status of α-synuclein and Parkinson's disease[J]. The Chinese Journal of Clinical Pharmacology, 2023, 39(8): 1201 - 1205. DOI: 10.13699/j.cnki.1001 - 6821.2023.08.029.

Subscription
E-Mail Alert
Most popular papers
Call for Special Issue
Publication Ethics & OA Statement
Plagiarism Policy
Contact Us
Downloads: 8494
Visits: 470889

Sponsors, Associates, and Links

All published work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2016 - 2031 Clausius Scientific Press Inc. All Rights Reserved.